QS Investors LLC grew its position in shares of Amgen (NASDAQ:AMGN) by 5.8% during the fourth quarter, Holdings Channel reports. The institutional investor owned 124,774 shares of the medical research company’s stock after buying an additional 6,863 shares during the quarter. QS Investors LLC’s holdings in Amgen were worth $21,698,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also recently added to or reduced their stakes in the company. Toronto Dominion Bank lifted its holdings in Amgen by 11.0% during the 3rd quarter. Toronto Dominion Bank now owns 279,280 shares of the medical research company’s stock worth $52,066,000 after buying an additional 27,726 shares during the last quarter. Teacher Retirement System of Texas lifted its holdings in Amgen by 16.5% during the 3rd quarter. Teacher Retirement System of Texas now owns 740,764 shares of the medical research company’s stock worth $138,115,000 after buying an additional 104,871 shares during the last quarter. Putnam FL Investment Management Co. bought a new position in Amgen during the 3rd quarter worth approximately $447,000. Moody Lynn & Lieberson LLC bought a new position in Amgen during the 3rd quarter worth approximately $2,353,000. Finally, Patten Group Inc. lifted its holdings in Amgen by 1,151.5% during the 3rd quarter. Patten Group Inc. now owns 27,859 shares of the medical research company’s stock worth $389,000 after buying an additional 25,633 shares during the last quarter. 79.54% of the stock is currently owned by institutional investors.
In related news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction that occurred on Thursday, April 12th. The stock was sold at an average price of $172.68, for a total value of $263,337.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Over the last 90 days, insiders sold 4,575 shares of company stock worth $818,330. 0.19% of the stock is owned by insiders.
A number of research firms have commented on AMGN. Leerink Swann reaffirmed a “market perform” rating on shares of Amgen in a report on Friday, February 2nd. Atlantic Securities downgraded Amgen from an “overweight” rating to a “neutral” rating and set a $187.01 price target on the stock. in a report on Monday, February 5th. BidaskClub raised Amgen from a “sell” rating to a “hold” rating in a report on Thursday, January 18th. Oppenheimer set a $205.00 price target on Amgen and gave the stock a “buy” rating in a report on Friday, January 5th. Finally, Credit Suisse Group raised their price target on Amgen from $191.00 to $194.00 and gave the stock a “neutral” rating in a report on Friday, February 2nd. Two research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and ten have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $190.57.
AMGN opened at $171.56 on Friday. Amgen has a 12 month low of $152.16 and a 12 month high of $201.23. The company has a debt-to-equity ratio of 1.35, a quick ratio of 5.17 and a current ratio of 5.49. The company has a market capitalization of $115,564.02, a P/E ratio of 13.64, a price-to-earnings-growth ratio of 2.12 and a beta of 1.36.
Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, February 1st. The medical research company reported $2.89 EPS for the quarter, missing the consensus estimate of $3.03 by ($0.14). Amgen had a net margin of 8.66% and a return on equity of 30.87%. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.84 billion. During the same quarter in the prior year, the business earned $2.89 earnings per share. The firm’s revenue was down 2.7% compared to the same quarter last year. research analysts expect that Amgen will post 13.28 earnings per share for the current fiscal year.
Amgen declared that its Board of Directors has initiated a stock repurchase plan on Thursday, February 1st that permits the company to buyback $10.00 billion in outstanding shares. This buyback authorization permits the medical research company to purchase shares of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board believes its shares are undervalued.
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 8th. Investors of record on Thursday, May 17th will be given a $1.32 dividend. This represents a $5.28 annualized dividend and a yield of 3.08%. The ex-dividend date of this dividend is Wednesday, May 16th. Amgen’s dividend payout ratio is currently 41.97%.
TRADEMARK VIOLATION WARNING: This story was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/22/amgen-amgn-shares-bought-by-qs-investors-llc.html.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.